Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-01

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study aims to explore the effectiveness of human erythropoietin versus placebo in promoting the recovery of erectile function in patients undergoing bilateral nerve-sparing radical retropubic prostatectomy for clinically localized prostate cancer.

Pre-clinical studies have shown erythropoietin potently promoted recovery of erectile function in rats and humans have similar receptors on penile tissues and the periprostatic neurovascular bundles. A clinical non-randomized study conducted in men undergoing radical prostatectomy demonstrated a benefit to recovery of erectile function.

Therefore, the hypothesis is that erythropoietin offers nerve protection in men undergoing nerve-sparing radical prostatectomy and results in a reduced degree of erectile dysfunction and also an improved rate of erection recovery following surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stem Cells for Erectile Dysfunction Post RALP

NCT07048314

Erectile Dysfunction Prostate Cancer

NOT_YET_RECRUITING PHASE1/PHASE2

MED3000 Topical Gel for On-Demand Treatment of Post-Radical Prostatectomy Erectile Dysfunction

NCT05673005

Erectile Dysfunction Following Radical Prostatectomy

COMPLETED NA

Erectile Dysfunction Study

NCT00873665

Erectile Dysfunction

COMPLETED NA

Efficacy of RestoreX Penile Traction Therapy In Preserving Erectile Function Post-Prostatectomy

NCT05244486

Erectile Dysfunction Following Radical Prostatectomy

RECRUITING NA

Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

NCT00955929

Penile Cancer Erectile Dysfunction Radical Prostatectomy

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will evaluate the effectiveness of erythropoietin versus placebo in the recovery of erectile function in patients undergoing bilateral nerve-sparing radical prostatectomy for prostate cancer.

Recent laboratory findings in rat models and on human urogenital tissues suggest that erythropoietin may play a role in protection of the cavernous nerves during surgery. Some degree of nerve trauma occurs during bilateral nerve-sparing radical prostatectomy, but for most it is temporary. Erythropoietin will be studied as an investigational drug for enhancement of erectile function postoperatively in a prospective, randomized study. Erythropoietin has been used in many men undergoing open radical prostatectomy in the past according to FDA indications for preparation for noncardiac, nonvascular surgery with a high risk of blood loss. Evidence also suggests it is safe with no demonstration of increased risk of venous thromboembolism (blood clots) or cardiac events for men with prostate cancer undergoing radical prostatectomy.

The length of the study is 12 months and involves receiving a dose of study drug or placebo on the day before surgery, the day of surgery, and the day following surgery. The dose is given by subcutaneous injection. The study will also require the completion of questionnaires which will be completed online every three months until study completion (at 3, 6, 9, and 12 months) to assess outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Erectile Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Erythropoietin (EPO)

20,000 units of EPO given on the day before surgery, the day of surgery, and the day after surgery.

Group Type EXPERIMENTAL

Erythropoietin (EPO)

Intervention Type DRUG

Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.

Placebo

Placebo doses given the day before surgery, the day of surgery, and the day after surgery.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.

Intervention Type DRUG

Erythropoietin (EPO)

Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient eligibility consists of men 40 to 65 years of age
* Localized prostate cancer

* clinical stage T2a or lower
* Gleason grade of 3+4 or 3+3
* prostate specific antigen (PSA) \< 10
* Scheduled to undergo curative prostatectomy applying bilateral nerve-sparing procedure, with intact pre-surgical erectile function
* International Index of Erectile Function-5 (IIEF-5) score of 22-25.
* The patient has a sexual partner, of at least 6 months.
* The patient's pre-surgical hematocrit is ≤ 48.
* The patient is willing to attempt intercourse at least 5 times per month following recovery from surgery.

Exclusion Criteria

* The patient has known penile deformity or a history of Peyronie's disease.
* The patient has planned pre or post operative androgen therapy.
* The patient has planned pre or post operative radiation therapy.
* The patient is on anticoagulation therapy.
* The patient has a history of sickle cell anemia.
* The patient has a history of high or low blood pressure that is not controlled.
* The patient is taking medications called "nitrates"
* The patient has a history of heart problems such as angina, heart failure, irregular heartbeats, or myocardial infarction
* The patient has a history of history of drug or alcohol abuse.
* The patient currently smokes or has a 20 pack/year history of cigarette smoking.
* The patient has a history of acute or chronic depression
* The patient has a history liver problems, or kidney problems.
* The patient has a history of retinitis pigmentosa or severe vision loss, including a condition called NAION, Nonarteritic Anterior Ischemic Optic Neuropathy.
* The patient has a history of spinal trauma or surgery to the brain or spinal cord.
* The patient has contraindications to the use of phosphodiesterase type 5 (PDE 5) inhibitors.
* Patient is currently participating in another clinical investigation that would serve as a contraindication to administering erythropoietin.

Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No